Clinical Trial Update: Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) [Phase 1]

View source ↗

Summary

Phase 1 trial of bendamustine plus alemtuzumab in refractory chronic lymphocytic leukemia and small lymphocytic lymphoma was terminated. The update notes the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)
• Treanda (Bendamustine)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia | Phase 1 | Status: TERMINATED